Press Release Friday 22 June 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Sativa share price movement
The Board of Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, notes the recent rise in the Company’s share price.
Whilst the Company has made investments to date, it is unaware of any specific reason for this recent movement.
The Board notes the significant increase in media and investor interest in the medical cannabis market, including the statement by the UK Home Secretary earlier this week highlighting the potential legalisation of cannabis for medicinal use in this country. As the UK’s only quoted medicinal cannabis company, the Board believes that Sativa is increasingly being viewed by the UK investment community as the de-facto UK investment vehicle for the sector, leading to the recent share price strength and enhanced demand for the Company’s shares.
Sativa would like to draw investor attention to the Company’s Admission Document, wherein Subscribers who participated in the Subscription at IPO undertook with the Company and Peterhouse, the Company’s Corporate Adviser and Broker, not to dispose of any interest in the Ordinary Shares held by them for a period of 12 months following Admission, which took place on 29 March 2018, in such manner as may reasonably be required without first consulting the Company and Peterhouse in order to maintain an orderly market in the Subscription Shares.
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: